Market Overview

WriteResult Brings Digital Pen ePRO to More Than 15 Industry Standard Assessments

Digital writing used to collect data from instruments such as: DLQI, EQ-5D™, SF-36®, HADS, VAS and Likert Scales.

Cranford, NJ (PRWEB) March 06, 2012

WriteResult announced today that their digital writing ePRO solution has been utilized with over 15 different health assessment questionnaires in over 30 languages to collect Patient-Reported Outcomes data in global clinical trials.

Instruments such as the DLQI, EQ-5D™, SF-36® (versions 1 and 2), Hospital Anxiety and Depression Scale (HADS), VAS Scales and Likert Scales are being collected by WriteResult's digital pen ePRO data management solution for several Phase III pivotal trials. Disease-specific forms, such as the Gout Assessment Questionnaire (GAQ) and the Psoriasis Quality of Life Questionnaire (PSORIQoL), have been collected using the digital pen ePRO platform for various therapy areas including Dermatology, Rheumatology, Inflammatory Disease and Pain.

Regardless of the specific PRO instrument, all the results are reconciled with other study data such as central lab or EDC data, and delivered to study sponsors as clean data ready for statistical analysis.

About WriteResult
WriteResult offers full-service data management solutions for clinical research through the collection and verification of ePROs leveraging digital pen and paper technology. Since 2006 WriteResult has partnered with study sponsors to deliver a simple and effective ePRO solution — rapid study startup with clean, real-time data using a technology that's intuitive for sites and patients.

For more information about WriteResult, please email solutions(at)writeresult(dot)com or call (908) 272-4787.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/3/prweb9257672.htm

 

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free